- Home
- LTRN vs ICCC Comparison
LTRN vs ICCC Comparison
Compare LTRN & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- ICCC
- Stock Information
- Founded
- LTRN 2013
- ICCC 1982
- Country
- LTRN United States
- ICCC United States
- Employees
- LTRN N/A
- ICCC N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- ICCC Health Care
- Exchange
- LTRN Nasdaq
- ICCC Nasdaq
- Market Cap
- LTRN 49.9M
- ICCC 55.5M
- IPO Year
- LTRN 2020
- ICCC 1987
- Fundamental
- Price
- LTRN $3.63
- ICCC $6.01
- Analyst Decision
- LTRN Strong Buy
- ICCC
- Analyst Count
- LTRN 1
- ICCC 0
- Target Price
- LTRN $25.00
- ICCC N/A
- AVG Volume (30 Days)
- LTRN 120.1K
- ICCC 21.7K
- Earning Date
- LTRN 11-14-2025
- ICCC 11-13-2025
- Dividend Yield
- LTRN N/A
- ICCC N/A
- EPS Growth
- LTRN N/A
- ICCC N/A
- EPS
- LTRN N/A
- ICCC 0.20
- Revenue
- LTRN N/A
- ICCC $28,274,756.00
- Revenue This Year
- LTRN N/A
- ICCC N/A
- Revenue Next Year
- LTRN N/A
- ICCC N/A
- P/E Ratio
- LTRN N/A
- ICCC $30.95
- Revenue Growth
- LTRN N/A
- ICCC 21.75
- 52 Week Low
- LTRN $2.55
- ICCC $3.38
- 52 Week High
- LTRN $6.12
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- LTRN 38.13
- ICCC 43.28
- Support Level
- LTRN $3.75
- ICCC $5.90
- Resistance Level
- LTRN $4.09
- ICCC $6.28
- Average True Range (ATR)
- LTRN 0.30
- ICCC 0.30
- MACD
- LTRN -0.04
- ICCC -0.03
- Stochastic Oscillator
- LTRN 5.95
- ICCC 13.95
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.